KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Jianming Xu, Lin Shen, Jie Li, Zhiwei Zhou, Chunmei Bai, Zhiping Li, Yihebali Chi, Enxiao Li, Xianjun Yu, Nong Xu, Yuxian Bai, Xiuwen Wang, Xianglin Yuan, Tianshu Liu, Yongmei Yin, Jia Chen, Hanguang Hu, Xingya Li, Dianrong Xiu, Tao Zhang, Wenhui Lou, Jieer Ying, Shukui Qin, Yanhong Deng, Min Tao, Ying Cheng, Songhua Fan, Xian Luo, Xiaojun Guo, Michael M Shi, Weiguo Su

Eur J Cancer 222 115398

PMID40306120
PMCID-
DOI10.1016/j.ejca.2025.115398
发表日期2025-04-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: SANET-ep (NCT02588170) and SANET-p (NCT02589821) demonstrated the efficacy and safety of surufatinib versus placebo in patients with advanced extra-pancreatic and pancreatic neuroendocrine tumours (NETs). Here, we present a pooled analysis of final overall survival (OS) from two randomised phase 3 studies. METHODS: The SANET studies were randomised, placebo-controlled, double-blind, phase 3 studies in China, comparing the efficacy and safety of oral 300-mg surufatinib (n = 265) versus placebo (n = 133) in patients with unresectable/metastatic, well-differentiated NETs (grade 1/2). After progression of disease or study unblinding, patients receiving placebo crossed over/switched to open-label surufatinib. By pooling the data from the two studies, OS analysis was completed using Kaplan-Meier methodology and a Cox proportional hazards model in the intention-to-treat population. Exploratory analyses were performed using different models to correct the confounding effect introduced by crossover. Long-term safety was assessed. RESULTS: At study termination, 69 % of the placebo group had crossed over/switched to surufatinib. Median OS was 50.1 versus 46.8 months for patients initially on surufatinib versus those initially on placebo (stratified hazard ratio [HR] 0.935, 95 % confidence interval [CI] 0.684-1.278; p = 0.6727). After correcting the confounding effect introduced by crossover/switching, the HR ranged from 0.558 to 0.825. Commonly (≥10 %) reported treatment-related adverse events (grade 3/4) included hypertension and proteinuria. CONCLUSION: OS of patients initially on surufatinib was not significantly longer versus patients initially on placebo, likely due to the high amount of crossover from placebo to surufatinib. No new safety signals were observed. CLINICAL TRIALS REGISTRATION: SANET-ep (NCT02588170) and SANET-p (NCT02589821).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。